Allergy Therapeutics (AGY) — Capital Reinvestment Ratio
Allergy Therapeutics (AGY) has a Capital Reinvestment Ratio of 0.31x as of December 2021, meaning it reinvests 0% of its operating cash flow (GBX3.71 Million) in capital expenditures (GBX1.15 Million). Check AGY goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Allergy Therapeutics Capital Reinvestment Ratio (2003–2021)
This chart tracks Allergy Therapeutics's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see Allergy Therapeutics operating cash flow efficiency.
Annual Capital Reinvestment Ratio for Allergy Therapeutics (2003–2021)
Year-by-year Capital Reinvestment Ratio for Allergy Therapeutics from 2003 to 2021. See AGY free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (GBX) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.30x | GBX8.52 Million | GBX2.56 Million | ▲ +45.0% |
| 2020 | 0.21x | GBX12.28 Million | GBX2.55 Million | ▼ -58.7% |
| 2019 | 0.50x | GBX5.60 Million | GBX2.81 Million | ▼ -94.0% |
| 2017 | 8.43x | GBX178.00K | GBX1.50 Million | ▲ +2312.2% |
| 2015 | 0.35x | GBX3.12 Million | GBX1.09 Million | ▼ -15.5% |
| 2014 | 0.41x | GBX2.17 Million | GBX898.00K | ▲ +22.4% |
| 2013 | 0.34x | GBX2.43 Million | GBX821.00K | ▼ -22.9% |
| 2012 | 0.44x | GBX2.88 Million | GBX1.26 Million | ▼ -56.1% |
| 2010 | 1.00x | GBX1.70 Million | GBX1.70 Million | ▲ +150.2% |
| 2004 | 0.40x | GBX1.91 Million | GBX760.00K | ▲ +105.8% |
| 2003 | 0.19x | GBX2.10 Million | GBX406.00K | — |